Clinical Trial Update: Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

View source ↗

Summary

A post-approval study of the R3 Biolox Delta Ceramic Acetabular System in Europe has completed, with results posted on 2024-05-30 for hip osteoarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hip Osteoarthritis

Drugs mentioned

• R3 Biolox Delta Ceramic Acetabular System

Snippet

Sponsor: Smith & Nephew Orthopaedics AG | Conditions: Degenerative Joint Disease of Hip | Status: COMPLETED | Results posted: 2024-05-30